No evidence for the use of stem cell therapy for tendon disorders: a systematic review

Haiko I M F L Pas,^{1,2} Maarten H Moen,^{1,3,4} Hidde J Haisma,⁵ Marinus Winters⁶

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bjsports-2016-096794>).

¹The Sports Physician Group, Department of Sports Medicine, OLVG West, Amsterdam, The Netherlands

²Department of Orthopaedic Surgery, Academic Medical Centre, Amsterdam, The Netherlands

³Bergman Clinics, Naarden, The Netherlands

⁴Department of Elite Sports, NOC*NSF, Medical Staff, Arnhem, The Netherlands

⁵Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, Groningen University, Groningen, The Netherlands

⁶Rehabilitation, Nursing Science and Sports Department, University Medical Centre Utrecht, Utrecht, The Netherlands

Correspondence to

Haiko IMFL Pas, Department of Orthopaedic Surgery, Academic Medical Centre, Meidreef 9, Amsterdam 1105AZ, The Netherlands; pas.haiko@gmail.com

Accepted 14 December 2016
Published Online First
11 January 2017

ABSTRACT

Introduction Stem cells have emerged as a new treatment option for tendon disorders. We systematically reviewed the current evidence for stem cell therapy in tendon disorders.

Methods Randomised and non-randomised controlled trials, cohort studies and case series with a minimum of 5 cases were searched in MEDLINE, CENTRAL, EMBASE, CINAHL, PEDro and SPORTDiscus. In addition, we searched grey literature databases and trial registers. Only human studies were included and no time or language restrictions were applied to our search. All references of included trials were checked for possibly eligible trials. Risk of bias assessment was performed using the Cochrane risk of bias tool for controlled trials and the Newcastle-Ottawa scale for case series. Levels of evidence were assigned according to the Oxford levels of evidence.

Results 4 published and three unpublished/pending trials were found with a total of 79 patients. No unpublished data were available. Two trials evaluated bone marrow-derived stem cells in rotator cuff repair surgery and found lower retear rates compared with historical controls or the literature. One trial used allogenic adipose-derived stem cells to treat lateral epicondylar tendinopathy. Improved Mayo Elbow Performance Index, Visual Analogue Pain scale and ultrasound findings after 1-year follow-up compared with baseline were found. Bone marrow-derived stem cell-treated patellar tendinopathy showed improved International Knee Documentation Committee, Knee injury and Osteoarthritis Outcome Score subscales and Tegner scores after 5-year follow-up. One trial reported adverse events and found them to be mild (eg, swelling, effusion). All trials were at high risk of bias and only level 4 evidence was available.

Conclusions No evidence (level 4) was found for the therapeutic use of stem cells for tendon disorders. The use of stem cell therapy for tendon disorders in clinical practice is currently not advised.

INTRODUCTION

Tendon disorders, in particular tendinopathy, is a frequently seen condition in athletes and in the general population.^{1–3} It is defined by localised swelling, pain and functional limitations of the affected tendon.⁴ Several therapies, such as eccentric exercises,⁵ non-steroidal anti-inflammatory drugs,⁶ shockwave therapy,^{7–9} corticosteroids,¹⁰ platelet-rich plasma^{11 12} and surgery⁶ have been used as treatments for tendinopathy, with variable levels of evidence and success. Despite some good results for some of these therapies,⁵ recalcitrant cases remain.

More recently, stem cells have entered the field of tendon disorder treatment. Several reviews have addressed the current evidence of cell therapy in tendinopathy and found that mostly small or large animal studies were available.^{13–18} Although in animal studies, there have been positive results in favour of stem cell treatment, clinical trials have been scarce and have shown only ‘encouraging results’.^{13–18}

The current model of chronic tendon disorders is based on a continuum of degeneration and failed healing^{19–21} with a yet unclear role of inflammatory cells.^{20 22–24} This model is mainly supported by histological findings with necrotic and apoptotic tenocytes, neovascularisation and collagen disarray.^{19 20} Within this model, the proposed mechanism of repair through stem cell use is twofold; first through these cells’ differentiating capabilities into new tenocytes they are proposed to generate new tendon tissue.^{13 18} Second, the paracrine effects of stem cells modulate the local immune response and stimulate repair in the surrounding cells by the production of growth factors and cytokines.^{12 25–28}

As more and more clinics arise that use stem cell treatments for a variety of conditions, including orthopaedic soft tissue disorders such as tendon disorders,²⁹ and with the increasing number of trials being published on this topic, we felt it was necessary to review the current evidence. Our aim was therefore to systematically review the efficacy of stem cell therapy for pain and functional outcomes in the treatment of tendon disorders in humans.

METHODS

We systematically searched for trials that investigated the effect of stem cell therapy of any kind in tendon disorders. Randomised and non-randomised controlled trials, cohort studies and case series with a minimum of five cases were searched. Complete selection criteria are reported in [box 1](#).

Search methods

With the help of a research librarian, a sensitive search strategy for multiple databases was developed by one author (MW) (see online supplementary appendix 1).

Using this strategy, one author (MW) searched all databases from the databases’ inception up to June 2016. We did not impose any restrictions on our search. We searched the following electronic databases: MEDLINE-PubMed, CENTRAL, EMBASE, CINAHL, PEDro and SPORTDiscus. Furthermore, possible unpublished and ongoing trials were

CrossMark

To cite: Pas HIMFL, Moen MH, Haisma HJ, et al. *Br J Sports Med* 2017;**51**:996–1002.

Box 1 Inclusion and exclusion criteria

Inclusion criteria

- ▶ Published and non-published *human* studies, randomised and non-randomised. Case series with ≥ 5 cases.
- ▶ Patients with tendon disorders diagnosed based on history and physical examination or imaging.
- ▶ Stem cells of any origin were used as treatment, minimal proof of stem cell presence was needed (eg, automated cell analysis, surface marker analysis, culturing, etc).
- ▶ In case of controlled trials, the effect must be compared with another treatment modality, placebo or no intervention.
- ▶ Had to report at least one of the following outcomes: time to recovery (or play), recurrences, patient-reported outcomes (PROMs), pain scales, adverse events.

Exclusion criteria

- ▶ Participants with tendinopathies and other concomitant injuries which were not separately assessed.

searched in OpenGrey; the British Library Inside; Web of Science and BIOSIS Previews and several international and national trial registers: the ISRCTN registry (<http://www.controlled-trials.com>), the WHO trial register (<apps.who.int/trialsearch>), EU clinical trial register (<http://www.clinicaltrialsregister.eu>); ClinicalTrials.gov and the Dutch trial register (<http://www.trialregisters.nl>). After inclusion of a trial, all references were hand searched for possible additional studies.

Study selection

After deletion of duplicates, two reviewers (HP and MW) independently scanned titles and abstracts of all identified studies. Full-text reports were obtained for potentially relevant studies. Both reviewers then independently applied the selection criteria (see box 1). In case of disagreement between reviewers, consensus was sought, and in case of persistent disagreement, a third party (MHM) was consulted.

Data extraction

Using a standardised data extraction sheet, two authors (HP and MW) independently extracted the following data: study design, study setting, inclusion/exclusion, details of the intervention (such as origin of stem cells used, cell isolation and culturing, dosage, frequency of administration, etc), primary and secondary outcome measures and adverse effects.

In case of disagreement, consensus was reached in a joint session. If no consensus could be reached, a third reviewer (MHM) was consulted.

Risk of bias assessment

Two reviewers (HP and MW) separately appraised the included studies for their quality. For randomised and non-randomised controlled trials, we used Cochrane Risk of Bias tool.³⁰ We appraised each study for the five major domains of bias: selection bias (random allocation and allocation concealment), performance bias (blinding of personnel and blinding of participants), detection bias (blinding of outcome assessment), attrition bias (follow-up adequacy), reporting bias (complete outcome reporting) and other biases. We adopted previously used criteria, formulated by Winters *et al*,³¹ to score each

domain (see online supplementary appendix 2). Each item was scored as to be at low (+), high (−) or unclear (?) risk of bias. Studies were considered to be at low risk of bias when all domains were scored as low (+) risk of bias, or one item was at high (−) or unclear (?) risk of bias (?). If two domains were scored as high (−) or unclear (?) risk of bias, the study was considered at moderate risk of bias. Finally, when more than two domains were scored as high (−) or unclear (?) risk of bias, the study was regarded as being at high risk of bias.

For case series, we used a modified version of the Newcastle-Ottawa quality assessment scale for cohort studies³² (see online supplementary appendix 3). A maximum of six stars could be achieved. No quality subdivision (ie, high, moderate, low risk of bias) was made for case series as these types of study are a priori at high risk of bias and a quality subdivision would not affect its level of evidence.

Data synthesis

We planned a data synthesis for randomised controlled trials (RCTs) (>2), when they were at low risk of bias and were clinically homogenous (ie, identical stem cell type and tendon disorder, cointerventions, mode of injection/transplantation). The mean difference was used for studies that used the same outcome measurement. Standardised mean differences were used for studies that used different outcome measures to estimate treatment effects. A p value <0.05 was considered significant for all analyses. We used a fixed effects model to pool data that were statistically homogenous, or when <5 studies were available for data synthesis. A random effects model was used when statistical heterogeneity was present (heterogeneity was considered present when the X^2 -test was significant, $p<0.1$), and when >5 studies were available for data synthesis. We visually inspected the forest plots and the heterogeneity statistic (I^2). If heterogeneity was present, and sufficient studies were available ($N\geq 10$), we planned a subgroup analysis or meta-regression analysis to explore the sources for heterogeneity.

If data pooling was not possible, we presented our findings by means of a descriptive synthesis using the levels of evidence approach based on the Oxford Centre for Evidence-based Medicine³³ (table 1). Systematic reviews were considered level 1 evidence, RCTs at low/moderate risk of bias or observational studies with a dramatic effect were considered level 2 of evidence, non-randomised controlled trials at low risk of bias at level 3 of evidence. Case series were considered as level 4 of evidence impact. Level 5 evidence was considered only when no studies were available and only mechanism-based reasoning was available. Studies were downgraded when they were at high risk of bias with the lowest level for studies being level 4.

Table 1 Oxford Centre for Evidence-based Medicine 2011 Levels of Evidence for interventions³³

Level 1	Systematic reviews
Level 2	Randomised controlled trials with low/moderate risk of bias or observational studies with dramatic effect
Level 3	Non-randomised controlled trials with low/moderate risk of bias or randomised controlled trials at high risk of bias
Level 4	Case series, case-control studies, historically controlled studies or non-randomised controlled trials at high risk of bias
Level 5	Mechanism-based reasoning/expert opinion

We did not prospectively register the protocol for our systematic review. However, the full protocol is available by email, from the corresponding author (HP).

RESULTS

Study selection

A total of 1043 articles were identified during our searches. After removal of duplicates, 684 singular articles were found. After title and abstract selection seven articles^{34–40} were selected for full-text evaluation (figure 1). Two trials^{37 39} were excluded because we were unable to determine whether stem cells had actually been injected as no analyses were performed to investigate whether stem cells were actually present. One article was excluded⁴⁰ because it was mostly *in vitro* and had no data of interest. One article³⁸ because it concomitantly injected platelet-rich plasma and included patients with osteoarthritis. Three articles^{34–36} met the inclusion criteria. Hand searching revealed no additional articles. One additional article⁴¹ was identified by hand searching previously published reviews evaluating stem cell use in tendon disorders.

Four possibly unpublished studies^{42–45} were identified but after contacting the principal investigators, no data were made available. One unpublished trial⁴² was found to be published³⁶ and had already been included in the results. Two unpublished trials^{43 45} were finalised at the time of writing the manuscript (June 2016). The final unpublished trial⁴⁴ was mentioned to be recruiting, but this could not be verified with the author.

Study characteristics

The characteristics of the included studies are summarised in table 2. One matched non-randomised study³⁵ and three case series were included for review.^{34 36 41}

A total of 79 patients were treated with two types of stem cells. The mean ages of the patients ranged from 24 to 61 years and the percentage of women ranged between 50% and 64%. Two studies^{34 35} evaluated the use of bone marrow-derived stem

cells as an additive treatment for rotator cuff repair. One study³⁶ investigated the use of allogenic adipose-derived stem cells in lateral epicondylar tendinopathy. The last study⁴¹ investigated the use of bone marrow-derived stem cells in patellar tendinopathy.

Harvesting methods were homogenous across the bone marrow-derived trials with collection occurring from the anterior iliac crest.^{34 35 41} After harvesting, the bone marrow aspirate was concentrated using a variety of techniques and then injected in the patient.^{34 35 41} None of these trials performed culturing or cell typing. One trial³⁵ confirmed the presence of stem cells by counting the number of colony-forming fibroblasts in the samples. One trial³⁴ counted the number of CD34 positive and mononuclear cells in its samples using flow cytometry. The last trial⁴¹ used uncharacterised nucleated cells obtained from bone marrow aspirations.

The remaining study³⁶ harvested allogenic adipose-derived stem cells from healthy donors' subcutaneous fat tissue. After aspiration, the lipoaspirate was purified and tested for viral, bacterial or fungal contamination. Culturing of the stromal vascular fraction was performed but the characterisation of stem cells was unclear. Before the cells were released for injection, a viable cell count was performed and purity of the cell line was assessed (80% viable cells and <1% CD45 positive cells as minimal criteria for release). Patients were injected locally using a double system syringe with fibrin clot to ensure local entrapment within a fibrin matrix.

Risk of bias

Three studies^{34 36 41} were assessed using the Newcastle-Ottawa scale and one³⁵ using the Cochrane Risk of bias tool. The motivation for the assessors' judgements can be found in online supplementary appendix 4.

The study by Hernigou *et al*³⁵ was found to be at high risk of bias (figure 2). All domains were at high or unclear risk of bias.

Figure 1 Selection process.

Table 2 Study characteristics

Author	Year	Study type	Lesion	n	Per cent of females	Mean age (range)	Last follow-up	Stem cell type	Culturing	Injection frequency	Mean number of cells
Lee <i>et al</i> ³⁶	2015	Case series	Lateral epicondylar tendinopathy	12	58	51.8 (9.5*)	52 weeks	Allogenic adipose-derived stem cells	Yes	1	10 ⁶ or 10 ⁷
Pascual-Garrido <i>et al</i> ⁴¹	2012	Case series	Patellar tendinopathy	8	50	24 (14–35)	5 years	Bone marrow mononuclear cells	No	1	45×10 ³
Hernigou <i>et al</i> ³⁵	2014	Matched non-randomised trial	Rotator cuff tear	2x 45	56	61 (49–71)	10 years	Bone marrow-derived stem cells	No	1	51×10 ³ ±25×10 ³
Ellera Gomez <i>et al</i> ³⁴	2012	Case series	Rotator cuff tear	14	64	59.2	12 months	Bone marrow mononuclear cells	No	1	5.65×10 ⁶ (CD34+, med) 3.81×10 ⁸ (mononuclear, med)

*SD.
med, median; n, number of patients in the study.

Figure 2 Risk of bias assessment using Cochrane risk of bias tool.

Owing to this high risk of bias the study was downgraded to level 4 evidence.

The number of stars awarded for case series ranged between two and four (figure 3). No quality subdivision was made. All studies lacked blinded outcome assessment and were unclear about the recruitment procedure.

Tendon disorder types and outcomes

Lateral epicondylar tendinopathy

One study³⁶ investigated the use of allogenic adipose-derived stem cells in 12 patients with lateral epicondylar tendinopathy. There were statistically significant positive results compared with baseline at all time points (6, 12, 26 and 52 weeks postinjection) for Visual Analogue Scale (VAS) scores ($p<0.001$), Mayo Elbow Performance Index (MEPI) ($p<0.001$) and ultrasound evaluation ($p<0.001$ for longitudinal and transverse axes) (table 3).

Patellar tendinopathy

One study⁴¹ reported the use of bone marrow-derived stem cells in eight cases of patellar tendinopathy. There were statistically significant improvements after an average 5-year (range 3–6) period for Tegner Activity Scale score (2–8, $p=0.006$), International Knee Documentation Committee (IKDC) (36–69, $p=0.047$) and for Knee injury and Osteo arthritis Outcome Score (KOOS) subdomains symptoms (44–71, $p=0.0086$), activities in daily living (63–90, $p=0.0086$) and sports (24–63, $p=0.0078$) (table 3). No statistical improvement were observed for Lysholm score (33–53, $p=0.1043$), KOOS pain (47–63, $p=0.2399$), KOOS quality of life (50–71, $p=0.0825$) and SF-12 mental and physical domains ($p=0.5589$ and $p=0.438$, respectively). On ultrasound evaluation, trends towards improvement were seen but these were not statistically evaluated.

Rotator cuff repair

Bone marrow-derived stem cells were injected at the tendon-bone junction of arthroscopic rotator cuff repairs in two studies.^{34 35} Combined, these two studies^{34 35} evaluated the results of 59 patients with stem cell injections. Both studies reported a reduced number of reruptures over time (table 3) compared either with historically selected controls³⁵ (6 vs 25 in favour of stem cell injection, $p<0.005$) or compared with the literature.³⁴ One study³⁴ reported improvement of mean University of California at Los Angeles shoulder rating scale scores (12 SD 3.0 preoperative vs 31 SD 3.2, 12 months postoperative), but no statistical analysis was performed. The latter study³⁵ did not report any functional or other outcomes besides reruptures. Stem cell-treated patients with and without reruptures were compared and a dose-response analysis found significantly less bone marrow mononuclear cells per cubic centimetre (1500+1200 vs 4200+1900, $p<0.01$) and less progenitor cells (14 000+9000 vs 54 000+23 000, $p<0.01$) in the grafts of patients with a rerupture.

Adverse events

Adverse events were reported in one trial.³⁶ No serious adverse events were reported. Mild swelling was seen in 50% of the participants within 48 hours postinjection which spontaneously subsided within 2 weeks. Two participants had ultrasonic evidence of joint effusion after 2 weeks. One case of delayed joint pain (7 weeks postinjection) was reported, which subsided with

Figure 3 Risk of bias assessment using Newcastle-Ottawa scale for cohort studies.

	Lee et al	Ellera-Gomez et al	Pascual-Garrido et al
1 Recruitment procedure			
2 Inclusion criteria	★		★
3 Ascertainment of exposure	★		★
4 Blinded outcome assessment			
5 Follow-up adequacy	★	★	
6 Intention-to-treat analysis	★	★	

Table 3 Study outcomes

Author	Year	Main outcomes	Significance	Level of evidence	Adverse events
Lee et al ³⁶	2015	VAS (0–100) at 6, 12, 24 and 52 weeks Modified mayo elbow performance index (MEPI) Largest defect area of common extensor origin tendon	p<0.001 p<0.001 p<0.001 (longitudinal and transverse)	4	6 cases of mild swelling with spontaneous resolution within 2 weeks, 2 cases of joint effusion after 1 month, resolved within 1 months, not significant. 1 case of delayed elbow pain treated with tramadol and acetaminophen
Pascual-Garrido et al ⁴¹	2012	Tegner Lysholm IKDC KOOS Pain Symptoms ADL Sport QOL SF-12 Mental Physical Ultrasound evaluation	p=0.0061 p=0.1043 p=0.047 p=0.2399 p=0.0086 p=0.0246 p=0.0078 p=0.0825 p=0.5589 p=0.438 NA. All patients had grade 2–3 before inoculation. 6/9 had grade 1 after 6 months, one patient had grade 3	4	Not reported
Hernigou et al ³⁵	2014	MRI assessment of cuff healing: Retears confirmed by MRI after 10 years Intervention: No change of MRI healing grade after 10 years: Mean cells success versus no success (retear): Bone marrow mononuclear cells Progenitor cells Non-healing in the first 6 months:	p<0.05 BMSC 6/45 vs control 25/45 NA BMSC 34/45 vs control 6/45 2.2 p<0.01 Success: 4200±1900/cm ³ vs no success: 1500±1200/cm ³ p<0.01 Success: 54 000±23 000/cm ³ vs no success: 14000±9000/cm ³ NA 0/45 intervention vs 8/45 control	4	Not reported
Ellera Gomez et al ³⁴	2012	UCLA score MRI analysis	NA, increase from 12 to 31 NA, 14 cases of full tendon integrity, 8/14 low signal intensity along supraspinatus, 11/14 high signal artefact at the bursal and tendon, 6/14 high signal intensity zone at the critical zone	4	Not reported

IKDC, International knee documentation committee; KOOS, Knee Injury and Osteoarthritis Outcome Score; NA, not available or applicable; SF-12, short form health survey 12; UCLA score, University of California at Los Angeles Shoulder rating scale; VAS, visual analogue scale.

rest and analgesics. No immunologic reactions were found based on CD4⁺ and CD8⁺ T cell ratio.

Summary

Four trials at high risk of bias (level 4 of evidence) were identified during this review. One case series³⁶ evaluated adipose-

derived stem cells in lateral epicondylar tendinopathy and found improvements in VAS, MEPI and ultrasound evaluations, when compared with baseline. One case series⁴¹ was available evaluating bone marrow-derived stem cells in patellar tendinopathy. It found improved Tegner, IKDC and KOOS subdomains compared with baseline but failed to find improvements in Lysholm,

SF-12 and other KOOS subdomains. One case series³⁴ and one non-RCT³⁵ were found evaluating bone marrow-derived stem cells in rotator cuff repair surgery. Historical controls were used in one trial³⁵ and reported a reduced retear rate. The other trial³⁴ reported lower retear rates compared with the literature and improved UCLA scores compared with baseline. One trial³⁶ reported adverse events. None of these adverse events were of grave nature.

DISCUSSION

We performed a systematic review to evaluate the body of evidence for the use of stem cells in tendon disorders. A total of four trials were found,^{34–36 41} only one³⁵ of which used a control group. Three unpublished trials^{43–45} were identified, two^{43 45} of which have been finalised. The use of stem cells was tested in patellar tendinopathy, lateral epicondylar tendinopathy and rotator cuff tears. Bone marrow-derived and allogenic adipose-derived stem cells were used. All trials were rated as level 4 evidence, making only level 4 evidence available for the efficacy of stem cell use in tendon disorders.

In lateral epicondylar tendinopathy, patellar tendinopathy and rotator cuff repairs improved healing evaluated through imaging modalities such as MRI or ultrasound, functional outcomes and pain scores were found compared with baseline. Ruptures of repaired rotator cuffs treated with stem cell injections peroperatively, were reduced when compared with the literature or historically selected controls. Safety was poorly reported as only one trial³⁶ reported adverse events but found them to be generally of mild nature such as transient pain, swelling or effusion.

Risk of bias in the identified trials

All trials were at high risk of bias and had major methodological limitations. First, only one trial included a control group³⁵ though it should be noted that this was a historically controlled study, consequently, no randomisation could be performed. Neither patients, personnel or outcome assessors were blinded to group allocation. This allowed for a high risk of selection, performance and detection bias. All other trials^{34 36 41} lacked a control group, allowing for alternative explanations of their positive results (eg, natural course, confounding, placebo). Lateral epicondylar tendinopathy, for example, is a benign condition, usually resolving within 12–18 months.^{9 46} It is possible that the ultrasound findings in the trial by Lee *et al*³⁶ are a result of natural healing. Ellera Gomez *et al*³⁴ compared the low retear rates with the literature, however, rupture rates vary greatly between studies.^{47 48} Given the small number of patients in this study, and a 0% rupture rate within 12 months, this may still lie within the normal distribution of probability.

The placebo effect might account for the positive results of Pascual-Garrido *et al*.⁴¹ The inclusion of non-adult participants (ie, <18 years) in this trial⁴¹ may also limit the generalisability of the study's findings to the adult population. We question the ethical soundness of highly experimental stem cell therapy in minors. Also, a high risk of selection and attrition bias seems to be present in this study; only patients who were able to complete the 2-year follow-up were included in the report.

Overall, due to high risk of bias across studies, all trials were assessed as level 4 evidence. Therefore, these results should be interpreted with great caution.

Stem cells have been used in medicine in attempts to treat a variety of conditions.^{49–54} Their use in tendinopathy is relatively new and this review critically examined the body of evidence in humans. It is now clear that the evidence to date is very poor with only highly biased trials reporting on the efficacy of stem

cell treatment. Previous reviews^{14–16} which included veterinary studies, have reported more trends towards efficacy but, as is the case with this review, all concluded that there is almost no evidence for stem cell therapy in the treatment of tendon disorders in humans. Three ongoing trials^{43–45} were found and we hope to review their results once they are published. Despite the fact that these trials may influence our results, we felt it was necessary to publish this result now considering the growing interest in this subject and the growing number of stem cell clinics.²⁹

Theoretical rationale for the use of stem cells to treat tendon disorders

Mesenchymal stem cells (MSCs) are defined as self-renewing and multipotent cells capable of differentiating into multiple cell types, including osteocytes, chondrocytes, adipocytes, hepatocytes, myocytes and cardiomyocytes.⁵⁵ MSCs were originally isolated from the bone marrow stroma but have also been identified also in other tissues, such as fat, epidermis and umbilical cord blood.^{56 57} The International Society for Cellular Therapy released a position statement in 2006⁵⁸ outlining the minimal criteria for defining MSCs: adherence to plastic, the presence of CD73, CD90 and CD105 antigen markers, absence of CD11b, CD14, CD19, CD34, CD45, CD79α and HLA class II and the ability to differentiate *in vitro*.

The mechanisms by which stem cells are proposed to repair injured tendons can be considered twofold. First, stem cells are proposed to differentiate into tenocytes and restart the healing process by differentiating into tenocytes.^{18 59 60} However, the fate of stem cells after injection is not well studied in tendon injury and research suggests that few cells remain *in situ* after implantation.^{14–16 25 61} Therefore, it is questionable whether there are enough cells to be of value for tendon repair. Second, the paracrine effect of stem cells is hypothesised to be beneficial for tissue repair.^{14 62 63} Several reviews^{25 63–67} have summarised the number of growth factors and cytokines that are secreted by MSCs and how these factors influence, often in animal models, the repair mechanisms of injured tendons. It should be noted that other injection therapies with growth factors, such as platelet-rich plasma, have mostly failed to demonstrate their efficacy within tendon disorder treatment.^{11 12 68}

Safety and quality of stem cell preparations

The MSCs used in the reviewed trials have not been found to be associated with malignancy.^{69 70} However, safety concerns remain an important issue for clinicians.⁶² Of the included trials, only one³⁶ reported adverse events, finding only mild adverse events within a 1-year follow-up. The remaining trials^{34 35 41} failed to report adverse events allowing for potentially dangerous side effects to have gone unnoticed.

Although all trials^{34–36 41} documented the mean number of injected stem cells, the ways of analysing the numbers and cell types varied across the studies. As mentioned earlier, specific criteria are available.⁵⁸ Of the included studies, only one trial³⁶ partially fulfilled these criteria. Ellera Gomez *et al*³⁴ used CD34 and mononuclear cell analysis, which is more specific for haematopoietic progenitor cells rather than bone marrow MSCs.^{55 58} The use of colony-forming unit counting by Hernigou *et al*³⁵ is a method that seems incomplete without surface marker analysis.⁷¹ Considering the above, the methods used by Pascual-Garrido *et al*⁴¹ also seem inadequate to properly confirm adequate stem cell numbers.

In three studies,^{34 35 41} stem cells concentrates were used and culturing was never performed. The mean number of injected cells varied widely with up to a factor of 1000 in difference

generally favouring culturing. Two studies^{35 36} analysed whether dosage played a role in the healing process. Lee *et al*³⁶ found no differences between 10^6 or 10^7 cells, Hernigou *et al*³⁵ found significantly lower number of stem cells and progenitor cells in patients with graft failures. The other two studies^{34 41} did not perform dosage analyses.

One concern with uncultured stem cell concentrates as used in the identified trials^{34 35 41} is the presence of multiple cell types.⁶² As to date there is no consensus^{62 72} regarding whether this non-cultured concentrating method is equally effective as the use of cultured stem cell implantation or injection, we cannot judge whether this is an important factor influencing the outcomes. Furthermore, we could not evaluate whether cell dose may play a role in possible therapeutic efficacy due to the heterogeneity in cell numbers, types of tendon disorders and the low number of participants.

Limitations

We excluded two trials^{37 39} that used bone marrow aspirates, and we discovered two other trials^{73 74} that made attempts to investigate stem cell efficacy in tendon disorders. All these trials were excluded because no analysis was performed to confirm the presence of potential stem cells in the intervention. We therefore believe their exclusion is justified, as inclusion would have created even more heterogeneity in this review. Furthermore, publication bias could not be investigated due to the small number of trials. This might mean that overly positive results are presented in our review. However, we aimed to control for publication bias as much as possible. We searched several grey literature databases and multiple trial registers to find all relevant existing studies investigating stem cell therapy in tendon disorders. Even though no protocol for this review was registered, we wrote and followed an a priori protocol which is freely available through the corresponding author (HP). Despite these limitations, we believe that this review provides the clinician with a good overview of the current evidence for using stem cells to treat of tendon disorders.

Future directions

As illustrated by this review, we are currently still a long way from being able to endorse, based on high-quality evidence, the addition of stem cells to the arsenal of possible treatments for tendon disorders. Many gaps in our knowledge about the efficacy, safety, administration route, timing of administration, dosage and consideration of mechanical stimulation^{13 60 75} are evident when reviewing the available literature. Future research has many questions to answer but more importantly, we believe that sound scientific investigations should be performed. As we illustrated with our risk of bias assessment, the current evidence is tainted with methodological flaws that allow for high risks of biased results. In the future, stem cell therapies should be tested RCTs, with appropriate characterisation of the cells, proper randomisation procedures and allocation concealment. Considering the results of currently available treatments like eccentric exercises,^{5 6} we believe it to be important to compare the possible efficacy of stem cell treatments with these currently accepted treatment modalities. Furthermore, studies should incorporate blinding of participants, personnel and outcome assessors. Adverse events should be recorded and reported in all cases. Finally, sample sizes should be large enough to find clinically relevant differences.

The above discussed shortcomings and concerns are in congruence with the findings of the recently published position statement of the Australasian College of Sports Physicians.⁶² On

the efficacy of stem cell treatment for tendinopathy they stated that there is a lack of evidence, which is a statement we believe to still hold true despite the availability of human trials. Furthermore, the concerns about long-term safety and poor research is one we share alike.

CONCLUSION

There is no evidence to support the use of stem cell therapy in tendon disorders. Overall, only level 4 evidence was found for the effectiveness of stem cells, and this is insufficient to recommend the use of stem cells of any kind in the treatment of any kind of tendon disorder. All studies are at high risk of bias and results must be replicated through good practice research before more general clinical implementation can be recommended.

What are the findings?

- The current level of evidence for stem cell use in tendon disorders is extremely poor.
- Only case reports or poorly designed trials are available.
- The results from the identified trials are at high risk of bias.

How might it impact on clinical practice in the future?

- The use of stem cell therapy for tendon disorders in clinical practice is not suitable outside of an appropriate ethics approved clinical trial.
- Patients seeking stem cell treatment for their tendon disorders can now be made aware of the lack of evidence and potential dangers.
- In cases where stem cells are used, safety must be monitored and reported by the investigator.

Acknowledgements The authors would like to thank Roos Steenhuis, research librarian, Onze Lieve Vrouwe Gasthuis West, Amsterdam, for her work in formulating their search.

Funding The Dutch National Olympic Committee.

Disclaimer The Dutch National Olympic Committee had no influence in the performance or publication of this review.

Competing interests HP and MW received a grant from the Dutch National Olympic Committee for the realisation of this review. HP reports receiving grants from the Dutch National Olympic Committee and the Sports Physician group, Department of Sports Medicine, OLVG West, Amsterdam, outside the submitted work.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- 1 Albers IS, Zwerver J, Diercks RL, *et al*. Incidence and prevalence of lower extremity tendinopathy in a Dutch general practice population: a cross sectional study. *BMC Musculoskelet Disord* 2016;17:16.
- 2 Ackermann PW, Renström P. Tendinopathy in sport. *Sports Health* 2012;4:193–201.
- 3 Maffulli N, Wong J, Almekinders LC. Types and epidemiology of tendinopathy. *Clin Sports Med* 2003;22:675–92.
- 4 Maffulli N, Khan KM, Puddu G. Overuse tendon conditions: time to change a confusing terminology. *Arthroscopy* 1998;14:840–3.
- 5 Murtaugh B, Ihm JM. Eccentric training for the treatment of tendinopathies. *Curr Sports Med Rep* 2013;12:175–82.
- 6 Andres BM, Murrell GA. Treatment of tendinopathy: what works, what does not, and what is on the horizon. *Clin Orthop Relat Res* 2008;466:1539–54.

- 7 Leal C, Ramon S, Furia J, *et al.* Current concepts of shockwave therapy in chronic patellar tendinopathy. *Int J Surg* 2015;24(Pt B):160–4.
- 8 van der Worp H, van den Akker-Scheek I, van Schie H, *et al.* ESWT for tendinopathy: technology and clinical implications. *Knee Surg Sports Traumatol Arthrosc* 2013;21:1451–8.
- 9 Sims SE, Miller K, Elfar JC, *et al.* Non-surgical treatment of lateral epicondylitis: a systematic review of randomized controlled trials. *Hand (N Y)* 2014;9:419–46.
- 10 Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. *Lancet* 2010;376:1751–67.
- 11 Tsikopoulos K, Tsikopoulos I, Simeonidis E, *et al.* The clinical impact of platelet-rich plasma on tendinopathy compared to placebo or dry needling injections: A meta-analysis. *Phys Ther Sport* 2016;17:87–94.
- 12 de Vos RJ, Windt J, Weir A. Strong evidence against platelet-rich plasma injections for chronic lateral epicondylar tendinopathy: a systematic review. *Br J Sports Med* 2014;48:952–6.
- 13 Lu YF, Chan KM, Li G, *et al.* Tenogenic differentiation of mesenchymal stem cells and noncoding RNA: From bench to bedside. *Exp Cell Res* 2016;341:237–42.
- 14 Lui PP. Stem cell technology for tendon regeneration: current status, challenges, and future research directions. *Stem Cells Cloning* 2015;7:163–74.
- 15 Lui PP, Ng SW. Cell therapy for the treatment of tendinopathy—a systematic review on the pre-clinical and clinical evidence. *Semin Arthritis Rheum* 2013;42:651–66.
- 16 Obaid H, Connell D. Cell therapy in tendon disorders: what is the current evidence? *Am J Sports Med* 2010;38:2123–32.
- 17 Valencia Mora M, Ruiz Ibán MA, Díaz Heredia J, *et al.* Stem cell therapy in the management of shoulder rotator cuff disorders. *World J Stem Cells* 2015;7:691–9.
- 18 Ruzzini L, Longo UG, Rizzello G, *et al.* Stem cells and tendinopathy: state of the art from the basic science to clinic application. *Muscles Ligaments Tendons J* 2012;2:235–8.
- 19 Xu Y, Murrell GA. The basic science of tendinopathy. *Clin Orthop Relat Res* 2008;466:1528–38.
- 20 Cook JL, Purdam CR. Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy. *Br J Sports Med* 2009;43:409–16.
- 21 Lui PP. Histopathological changes in tendinopathy—potential roles of BMPs? *Rheumatology (Oxford)* 2013;52:2116–26.
- 22 Rees JD, Stride M, Scott A. Tendons—time to revisit inflammation. *Br J Sports Med* 2014;48:1553–7.
- 23 Battery L, Maffulli N. Inflammation in overuse tendon injuries. *Sports Med Arthrosc* 2011;19:213–17.
- 24 Fredberg U, Stengaard-Pedersen K. Chronic tendinopathy tissue pathology, pain mechanisms, and etiology with a special focus on inflammation. *Scand J Med Sci Sports* 2008;18:3–15.
- 25 Nixon AJ, Watts AE, Schnabel LV. Cell- and gene-based approaches to tendon regeneration. *J Shoulder Elbow Surg* 2012;21:278–94.
- 26 Guevara-Alvarez A, Schmitt A, Russell RP, *et al.* Growth factor delivery vehicles for tendon injuries: Mesenchymal stem cells and Platelet Rich Plasma. *Muscles Ligaments Tendons J* 2014;4:378–85.
- 27 Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. *J Cell Biochem* 2006;98:1076–84.
- 28 Pers YM, Ruiz M, Noël D, *et al.* Mesenchymal stem cells for the management of inflammation in osteoarthritis: state of the art and perspectives. *Osteoarthritis Cartilage* 2015;23:2027–35.
- 29 Turner L, Knoepfler P. Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. *Cell Stem Cell* 2016;19:154–7.
- 30 Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
- 31 Winters M, Eskes M, Weir A, *et al.* Treatment of medial tibial stress syndrome: a systematic review. *Sports Med* 2013;43:1315–33.
- 32 Wells GA, Shea B, O'Connell D, *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 22 Apr 2016).
- 33 Group OLoEW. The Oxford Levels of Evidence 2. 2011. <http://www.cebm.net/ocebml-levels-of-evidence/> (accessed 22 Apr 2016).
- 34 Ellera Gomes JL, da Silva RC, Silla LM, *et al.* Conventional rotator cuff repair complemented by the aid of mononuclear autologous stem cells. *Knee Surg Sports Traumatol Arthrosc* 2012;20:373–7.
- 35 Herrigou P, Flouzat Lachaniette CH, Delambre J, *et al.* Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study. *Int Orthop* 2014;38:1811–18.
- 36 Lee SY, Kim W, Lim C, *et al.* Treatment of Lateral Epicondylitis by Using Allogeneic Adipose-Derived Mesenchymal Stem Cells: A Pilot Study. *Stem Cells* 2015;33:2995–3005.
- 37 Moon YL, Jo SH, Song CH, *et al.* Autologous bone marrow plasma injection after arthroscopic debridement for elbow tendinosis. *Ann Acad Med Singapore* 2008;37:559–63.
- 38 Centeno CJ, Al-Sayegh H, Bashir J, *et al.* A prospective multi-site registry study of a specific protocol of autologous bone marrow concentrate for the treatment of shoulder rotator cuff tears and osteoarthritis. *J Pain Res* 2015;8:269–76.
- 39 Stein BE, Stroh DA, Schon LC. Outcomes of acute Achilles tendon rupture repair with bone marrow aspirate concentrate augmentation. *Int Orthop* 2015;39:901–5.
- 40 Broese M, Toma I, Haasper C, *et al.* Seeding a human tendon matrix with bone marrow aspirates compared to previously isolated hBMSCs—an in vitro study. *Technol Health Care* 2011;19:469–79.
- 41 Pascual-Garrido C, Rolón A, Makino A. Treatment of chronic patellar tendinopathy with autologous bone marrow stem cells: a 5-year-followup. *Stem Cells Int* 2012;2012:953510.
- 42 Chung SC. Treatment of Tendon Injury Using Mesenchymal Stem Cells (ALLO-ASC), NCT01856140. <https://clinicaltrials.gov/show/NCT01856140>
- 43 Chung SG. Treatment of Tendon Injury Using Allogeneic Adipose-derived Mesenchymal Stem Cells (Rotator Cuff Tear), NCT02298023. <https://clinicaltrials.gov/show/NCT02298023>
- 44 Goldberg A. Autologous Stem Cells in Achilles Tendinopathy (ASCAT), NCT02064062. <https://clinicaltrials.gov/show/NCT02064062>
- 45 Gutierrez BF. Mesenchymal Stem Cell (MSC) Included in OrthoADAPT Membrane for Rotator Cuff Tears Repair (mstendonrep), NCT01687777. <https://clinicaltrials.gov/show/NCT01687777>
- 46 Ahmad Z, Siddiqui N, Malik SS, *et al.* Lateral epicondylitis: a review of pathology and management. *Bone Joint J* 2013;95-B:1158–64.
- 47 Slabaugh MA, Nho SJ, Grumet RC, *et al.* Does the literature confirm superior clinical results in radiographically healed rotator cuffs after rotator cuff repair? *Arthroscopy* 2010;26:393–403.
- 48 Randelli P, Spennacchio P, Ragone V, *et al.* Complications associated with arthroscopic rotator cuff repair: a literature review. *Musculoskelet Surg* 2012;96:9–16.
- 49 Compagna R, Amato B, Massa S, *et al.* Cell Therapy in Patients with Critical Limb Ischemia. *Stem Cells Int* 2015;2015:931420.
- 50 Filardo G, Perdida F, Roffi A, *et al.* Stem cells in articular cartilage regeneration. *J Orthop Surg Res* 2016;11:42.
- 51 Fisher SA, Zhang H, Doree C, *et al.* Stem cell treatment for acute myocardial infarction. *Cochrane Database Syst Rev* 2015;(9):CD006536.
- 52 Kulak-Bejda A, Kulak P, Bejda G, *et al.* Stem cells therapy in cerebral palsy: A systematic review. *Brain Dev* 2016;38:699–705.
- 53 Peruzzi M, De Falco E, Abbate A, *et al.* State of the Art on the Evidence Base in Cardiac Regenerative Therapy: Overview of 41 Systematic Reviews. *Biomed Res Int* 2015;2015:613782.
- 54 Wormald JC, Fishman JM, Juniāt S, *et al.* Regenerative medicine in otorhinolaryngology. *J Laryngol Otol* 2015;129:732–9.
- 55 Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. *Arthritis Res Ther* 2007;9:204.
- 56 Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views. *Stem Cells* 2007;25:2896–902.
- 57 Gnecci M, Melo LG. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. *Methods Mol Biol* 2009;482:281–94.
- 58 Dominici M, Le Blanc K, Mueller I, *et al.* Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006;8:315–17.
- 59 Mautner K, Blazuk J. Where do injectable stem cell treatments apply in treatment of muscle, tendon, and ligament injuries? *PM R* 2015;7(4 Suppl):S33–40.
- 60 Gaspar D, Spanoudes K, Holladay C, *et al.* Progress in cell-based therapies for tendon repair. *Adv Drug Deliv Rev* 2015;84:240–56.
- 61 Guest DJ, Smith MR, Allen WR. Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study. *Equine Vet J* 2008;40:178–81.
- 62 Osborne H, Anderson L, Burt P, *et al.* Australasian College of Sports Physicians-position statement: the place of mesenchymal stem/stromal cell therapies in sport and exercise medicine. *Br J Sports Med* 2016;50:1237–44.
- 63 Ahmad Z, Henson F, Wardale J, *et al.* Review article: Regenerative techniques for repair of rotator cuff tears. *J Orthop Surg (Hong Kong)* 2013;21:226–31.
- 64 Liu H, Zhu S, Zhang C, *et al.* Crucial transcription factors in tendon development and differentiation: their potential for tendon regeneration. *Cell Tissue Res* 2014;356:287–98.
- 65 Branford OA, Klass BR, Grobbelaar AO, *et al.* The growth factors involved in flexor tendon repair and adhesion formation. *J Hand Surg Eur Vol* 2014;39:60–70.
- 66 Bedi A, Maak T, Walsh C, *et al.* Cytokines in rotator cuff degeneration and repair. *J Shoulder Elbow Surg* 2012;21:218–27.
- 67 Meirelles Lda S, Fontes AM, Covas DT, *et al.* Mechanisms involved in the therapeutic properties of mesenchymal stem cells. *Cytokine Growth Factor Rev* 2009;20:419–27.

- 68 de Vos RJ, van Veldhoven PL, Moen MH, *et al.* Autologous growth factor injections in chronic tendinopathy: a systematic review. *Br Med Bull* 2010;95:63–77.
- 69 Casiraghi F, Remuzzi G, Abbate M, *et al.* Multipotent mesenchymal stromal cell therapy and risk of malignancies. *Stem Cell Rev* 2013;9:65–79.
- 70 Lalu MM, McIntyre L, Pugliese C, *et al.* Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. *PLoS ONE* 2012;7:e47559.
- 71 Sensebé L, Bourin P, Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells. *Hum Gene Ther* 2011;22:19–26.
- 72 Sampson S, Botto-van Bemden A, Aufiero D. Autologous bone marrow concentrate: review and application of a novel intra-articular orthobiologic for cartilage disease. *Phys Sportsmed* 2013;41:7–18.
- 73 Yoon JP, Chung SW, Kim JY, *et al.* Outcomes of Combined Bone Marrow Stimulation and Patch Augmentation for Massive Rotator Cuff Tears. *Am J Sports Med* 2016;44:963–71.
- 74 Singh A, Gangwar DS, Singh S. Bone marrow injection: A novel treatment for tennis elbow. *J Nat Sci Biol Med* 2014;5:389–91.
- 75 Chen JL, Zhang W, Liu ZY, *et al.* Physical regulation of stem cells differentiation into teno-lineage: current strategies and future direction. *Cell Tissue Res* 2015;360:195–207.